Skip to content
Stay curious ↗

Follow your curiosity.

Try “brain”, “genomics”, or another subject you follow.

Today/Rare Diseases
Rare Diseases · The big question

FDA Halts Prader-Willi Drug Trial Over Heart Safety Concerns

FDA hold puts Aardvark Prader-Willi drug in limbo

BioPharma Dive1 min readAI-assisted summary
Editorial illustration for FDA hold puts Aardvark Prader-Willi drug in limbo
Editorial illustration

Summary

Prader-Willi syndrome is a rare genetic condition that causes intense, nonstop hunger, a symptom medically known as hyperphagia. To help patients manage this constant urge to eat, a biotech company named Aardvark developed an experimental drug called ARD-101. The medication works by triggering the release of two naturally occurring gut hormones, GLP-1 and cholecystokinin, which send signals to the brain to increase feelings of fullness.

Unfortunately, the development of this treatment has hit a major roadblock. The Food and Drug Administration recently placed a clinical hold on the late-stage study of ARD-101 due to serious safety concerns. Researchers observed cardiovascular complications in patients taking an 800-milligram twice-daily dose of the medication. Because of these heart-related issues, the trial is completely paused, underscoring the high-risk nature of the drug program.

To figure out the next steps, Aardvark must now unblind the study. This means researchers will finally look at the hidden trial data to see which patients received the actual drug and which received a placebo. Moving forward, the FDA will likely require the company to design and run new studies using a lower dose to better protect patient safety.

Why it matters.

Finding effective treatments for Prader-Willi syndrome has historically been a massive challenge for drug developers, leaving patients and their families with very few options to manage life-threatening overeating. If Aardvark can successfully identify a lower, safer dose that still effectively controls hunger, ARD-101 could become a crucial tool for this vulnerable patient population.

However, the clinical hold places Aardvark in a precarious financial position. The company currently holds $90 million in cash reserves, a supply expected to run out by mid-2027. If Aardvark cannot quickly agree with the FDA on a new, safer trial design, it faces a severe funding shortfall. This setback highlights the fragile reality of biotech drug development, where unexpected safety issues can quickly jeopardize promising medical breakthroughs.

From the source

The story in numbers.

Current twice-daily dose
800 milligram
Share price decline
36%
Estimated cash reserves
$90 million
Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

Your next discovery.

Keep exploring ↗
Rare Diseases

A Potential First Treatment for Stiff Person Syndrome

People living with stiff person syndrome currently have zero approved medicines designed specifically to treat their condition. However, a glimmer of hope is on the horizon. A biotechnology company named Kyverna Therapeutics is actively nearing regulatory approval for a new approach to managing the disease. This proposed treatment relies on CAR-T cell therapy. In this type of medicine, scientists take a patient's own immune cells and genetically modify them in a laboratory so they can track down and eliminate specific disease-causing cells in the body. While traditionally known as a powerful tool against certain blood cancers, researchers are now applying this advanced technology to complex neurological and autoimmune disorders. Although the prospect of a first-ever approved treatment is exciting, the medical community is still waiting on the fine print. Current reports are brief and lack the detailed clinical data needed to fully evaluate the medicine. Crucial details regarding how many patients were tested, the potential side effects, and exact measurements of how well the therapy works have not yet been fully disclosed to substantiate the impending approval.

Labiotech.eu1 min read
Rare Diseases

How a tiny worm solved a genetic mystery in a rare brain disorder

Our brain cells communicate by passing chemical signals, a process controlled by tiny gates called ion channels. When the genes instructing these gates carry a mutation, it can cause severe neurological disorders. Generally, doctors classify these mutations into two straightforward categories. A loss-of-function mutation means the gates are closed or broken, while a gain-of-function mutation means the gates are stuck open. However, researchers recently encountered a patient with a mutation in a calcium channel gene called CACNA1A whose symptoms bafflingly fit into both categories at once. To solve this clinical mystery, scientists first tested the mutation in standard lab dishes using isolated cells. This traditional method completely missed the dual nature of the disease, falsely indicating that the mutation only caused a severe loss of channel function. Realizing they needed a more complete picture, the team engineered the exact genetic variant into a microscopic worm called C. elegans to observe the mutation in a living nervous system. The worms revealed a fascinating paradox. Even though the mutation resulted in fewer calcium channels overall, the channels that did exist misbehaved. Computer simulations and electrical recordings showed that the faulty gates lingered in a partially open state, allowing calcium to leak into the cells while they were supposed to be resting. This constant leak triggered an unwanted release of chemical signals, perfectly explaining how a single mutation could cause such a confusing mix of clinical symptoms.

bioRxiv2 min read
Rare Diseases

New Drug Shows Early Promise for Rare Vascular Diseases

A new experimental drug called zovegalisib is showing early promise for patients with rare blood vessel conditions known as vascular anomalies and PROS. Developed by Relay Therapeutics, the medication works by blocking a specific genetic target called PIK3CA, an enzyme that is often involved in abnormal tissue growth. In early testing, zovegalisib has demonstrated striking results compared to the current standard treatment, Novartis' drug Vijoice. While the older medication historically shrinks tissue overgrowths in 11 to 27 percent of patients, Relay's new drug achieved response rates of 43 percent at lower doses and a remarkable 100 percent at higher doses. Beyond working more effectively, it also appears to be much gentler on patients. Severe side effects occurred in just 9 percent of those taking zovegalisib, a sharp drop from the 30 to 71 percent severe side effect rate seen in previous studies of Vijoice. However, researchers caution that these findings come from an early-stage clinical trial. Scientists still need to conduct additional testing using different dosing schedules to find the perfect balance between keeping the drug highly effective and maintaining its strong safety profile.

BioPharma Dive1 min read

A little science goes a long way.

Clear, thoughtful biotech briefings. In your inbox three times a week.

Stay curious. Subscribe free ↗